Chordate Medical’s CEO, Anders Weilandt, recently returned from Saudi Arabia and the United Arab Emirates, where he met with both existing and potential clients, and signed an agreement with a new marketing agent for the UAE.
“It has been a rewarding week where, together with our General Manager for GCC, Alain Durante, and Janin Medical, we met several healthcare organizations interested in Ozilia. We also visited IMC International Medical Center Jeddah, which has been treating rhinitis with Ozilia for a long time, and Nadicare Clinics with now six sites around Jeddah, which recently started using Ozilia on the first clinic,” says Anders Weilandt.
The Gulf region has long been one of Chordate’s priority markets to demonstrate proof of concept, and Ozilia has been used by several private hospitals for the treatment of rhinitis for an extended period.
“It is clear that the demand for treatments like Ozilia is significant in the region, and after the gradual establishment of the rhinitis treatment in the market, the next step is to launch Ozilia for chronic migraine and simultaneously bring in more clients on the rhinitis side,” says Anders Weilandt.
